US Patent

US10925832 — Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation

Formulation · Assigned to Karuna Therapeutics Inc · Expires 2039-09-27 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an oral pharmaceutical composition containing xanomeline and trospium beads.

USPTO Abstract

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Drugs covered by this patent

Patent Metadata

Patent number: US10925832
Jurisdiction: US
Classification: Formulation
Expires: 2039-09-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Karuna Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.